LDL Cholesterol, Statins and PCSK 9 Inhibitors

Indian Heart Journal

Volumn 67, Issue 5, 2015, Pages 419-424

  Gupta, Sanjiv ^a  

^a SDM Hospital   (India)

Author keywords

ASCVD; LDLc; PCSK 9 inhibitors; Statin

Indexed keywords

ALIROCUMAB; AMINOTRANSFERASE; BOCOCIZUMAB; ENZYME INHIBITOR; EVOLOCUMAB; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; NICOTINIC ACID; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 INHIBITOR; SIMVASTATIN; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ACUTE PANCREATITIS; ARTHRALGIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHEMOPROPHYLAXIS; CORONARY ARTERY ATHEROSCLEROSIS; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; FLU LIKE SYNDROME; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; INJECTION SITE REACTION; MUSCLE DISEASE; MYOGLOBINURIA; MYOSITIS; NAUSEA; REVIEW; RHABDOMYOLYSIS; RHINOPHARYNGITIS; SIDE EFFECT; UNSTABLE ANGINA PECTORIS; ANTAGONISTS AND INHIBITORS; BLOOD;

ANTIBODIES, MONOCLONAL, HUMANIZED; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; PROPROTEIN CONVERTASE 9;

EID: 84942837392     PISSN: 00194832     EISSN: 22133763     Source Type: Journal    
DOI: 10.1016/j.ihj.2015.05.020     Document Type: Review

References (39)

1. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults - executive summary of the third report of the national cholesterol education programme (NCEP). Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult treatment panel III) J Am Med Ass 285 2001 2486 2497
2. J.H. O' Keefe Jr., L. Cordain, W.H. Harris, R.M. Moe, and R. Vogel Optimal low density lipoprotein is 50-70 mg/dl; lower the better and physiologically normal J Am Coll Cardiol 43 2004 2142 2146
3. C. Baigent, L. Blackwell, J. Emberson, et al. for the Cholesterol Treatment Trialist (CTT) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta analysis of data from 170,000 participants in 26 randomized trials Lancet 376 2010 1670 1681
4. S.S. Martin, R.S. Blumenthal, and M. Miller LDL cholesterol: the lower the better Med Clin N Am 96 2012 13 26
5. N.J. Stone, J.G. Robinson, A.H. Lichtenstein, and et al. 2013 ACC/AHA guidelines on treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults J Am Coll Cardiol 63 2014 2889 2934
6. D.C. Goff Jr., D.M. Lloyd-Jones, G. Bennet, and et al. 2013 ACC/AHA guidelines on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 63 2014 2935 2959
7. National Institute for Health and care Excellence (NICE): Lipid Modification, Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease. Available at: http://www.nice.org/UK/guidance/index.
8. A.L. Catapano, Z. Reiner, G. De Backer, and et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dsylipidaemias for the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Atherosclerosis 217 2011 3 46
9. T.J. Anderson, J. Greogoire, R.A. Hegele, and et al. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidaemia for the prevention of cardiovascular disease in adults Can J Cardiol 29 2013 151 167
10. S.S. Martin, T.T. Abd, S.R. Jones, and et al. 2013 ACC/AHA cholesterol treatment guidelines. What was done well and what could be done better J Am Coll Cardiol 63 2014 2674 2678
11. D.M. Lloyd Jones, D. Goff, and N.J. Stone Statins, risk assessment and the new American prevention guidelines Lancet 383 2014 600 602
12. T.M. Maddox, W.B. Borden, F.T. Tang, and et al. Implications of the 2013 ACC/AHA cholesterol guidelines for adults in contemporary cardiovascular practice - insight from the NCDR Pinnacle registry J Am Coll Cardiol 64 2014 2183 2195
13. K. Sarat Chandra, M. Bansal, T. Nair, and et al. Consensus statement on management of dyslipidemia in Indian subjects Indian Heart J 66 suppl 3 2014 S1 S51
14. Standards of medical care in diabetes Diabetes Care 37 2014 S14 S80
15. P.C. Deedwania, M. Gupta, M. Stein, J. Ycas, and A. Gold Comparison of rosuvastatin versus atorvastatin in south Asian patients at risk of coronary artery disease Am J Cardiol 99 2007 1538 1543
16. S. Ahmed, G.P. Cannon, S.A. Murphy, and et al. Acute coronary syndromes and Diabetes: is intensive lipid lowering, beneficial? Result of the PROVE IT - TIMI 22 Trial Eur Heart J 27 2006 2323 2329
17. AIM HIGH Investigators W.E. Boden, and J.L. Probstfeld Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy New Engl J Med 365 2011 2255 2267
18. J.J. Albers, A. Slee, K.D. O'Brien, and et al. Relationship of Apo lipoprotein A-1 and B, and Lipoprotein (a) to cardiovascular outcomes. The AIM HIGH TRIAL (Atherosclerosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes) J Am Coll Cardiol 62 2013 1575 1579
19. Improved Reduction of Outcome: Vytorin Efficacy International Trial Presented by Dr. Christopher Cannon at AHA Scientific Session Nov 17, 2014.
20. M. Cuchel, E.A. Meagher, H. du Toit Theron, and et al. Efficacy and safety of microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolemia: a single arm, open label phase 3 study Lancet 381 2013 40 46
21. G.S. Thomas, W.C. Cromwell, S. Alis, W. Chin, I.D. Flaim, and M. Davidson Mipomersen an apoprotein B synthesis inhibitor reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk - a randomized, double blind, placebo controlled trial J Am Coll Cardiol 62 2013 2178 2184
22. M. Abifadel, M. Varret, J.P. Rabes, and et al. Mutations in PCSK 9 causes autosomal dominant hypercholestermia Nat Genet 34 2003 154 156
23. G. Lambert, F. Petrides, M. Chatelais, and et al. Elevated plasma PCSK 9 levels are equally detrimental for patients with non familial hypercholestremia and heterozygous familial hypercholesterolemia irrespective of low density lipoprotein receptor defects J Am Coll Cardiol 63 2014 2365 2375
24. D. Urban, J. Poss, M. Bohn, and S. Lauf Targeting the Proprotein Convertase Subtilisin/Kexin Type 9 for treatment of dyslipidemia and atherosclerosis J Am Coll Cardiol 62 2013 1401 1408
25. Razvan T. Dadu, and Chrislie Ballantyne Lipid lowering with PCSK 9 inhibitors Nat Rev Cardiol 11 2014 563 575
26. A.D. Snider, S. Tsimikans, and S. Fazio The severe hypercholesterolemia phenotype J Am Coll Cardiol 63 2014 1935 1947
27. M.J. Koren, R. Scott, J.B. Kin, and et al. Efficacy, safety and tolerability of monoclonal antibody to proprotein convertase subtilisin/Kexin type 9 as monotherapy in patients with hypercholesterolemia (MENDEL): a randomized, double blind, placebo controlled, phase 2 study Lancet 380 2012 1995 2006
28. F. Raal, R. Scott, R. Somaratne, and et al. Low density lipoprotein cholesterol lowering effect of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/Kexin type 9 serine proteases in patients with heterozygous familial hypercholesterolemia: the Reduction of LDLc with PCSK 9 inhibitors in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial Circulation 126 2012 2408 2417
29. D. Sullivan, A.G. Olsson, R. Scott, and et al. Effects of a monoclonal antibody to PCSK 9 on low density lipoprotein cholesterol levels in statin intolerant patients: the GAUSS randomized trial J Am Med Ass 308 2012 2497 2506
30. M.J. Koren, P. Lundqvist, M. Blognese, and et al. Anti PCSK 9 monotherapy for hypercholesterolemia - the MANDEL 2, randomized, controlled phase III clinical trial of evolocumab J Am Coll Cardiol 63 2014 2531 2540
31. E. Stroes, D. Colquhoun, D. Sullivan, and et al. Anti PCSK 9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS 2 randomized, placebo controlled phase 3 clinical trial of evolocumab J Am Coll Cardiol 63 2014 2541 2548
32. N.R. Desai, P. Kohli, R.P. Giugliano, and et al. AMG 145, a monoclonal antibody against proprotein convertase subtilisin kexin 9 significantly reduces lipoprotein (a) in hypercholesterolemia patients receiving statin therapy: an analysis from the LDL Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE) Thrombolysis in Myocardial Infarction TIMI 57 trial Circulation 128 2013 962 969
33. M.J. Koren, R.P. Giugliono, F. Raas, and et al. Efficacy and safety of longer term administration of evolocumab (AMC 145) in patients with hypercholesterolemia: 52 weeks results from the open label study of Long Term Evaluation against LDLc (OSLER) randomized trial Circulation 129 2014 234 243
34. J.J. Raal, R.P. Giugliano, M.S. Sabatine, and et al. Reduction in lipoprotein (a) with PCSK 9 monoclonal antibody evolocumab (AMG 145) J Am Coll Cardiol 63 2014 1278 1288
35. E.A. Stein, N. Honarpour, S.M. Wasserman, F. Xu, R. Scott, and J.J. Raal Effects of the lipoprotein convertase subtilisin/Kexin 9 monoclonal antibody AMG 145 in homozygous familial hypercholestermia Circulation 128 2013 2113 2120
36. E.A. Stein, D. Gipe, J. Bergeron, and et al. Effects of a monoclonal antibody to PCSK 9 Reg N 727/SAR 236553 to reduce low density lipoprotein cholesterol in patients with heterozygous familial hypercholestremia on stable statin dose with or without ezetimibe therapy: a phase 2 randomized controlled trial Lancet 380 2012 29 36
37. E.M. Roth, J.M. McKenny, C. Hanotin, G. Asset, and E.A. Stein Atorvastatin with without an antibody to PCKS 9 in primary hypercholesterolemia New Engl J Med 367 2012 1891 1900
38. J.M. McKeeny, M.J. Koren, D.J. Keveiakes, C. Flanotin, X.C. Ferrand, and E.A. Stein Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/Kexin type 9 serine protease SAR 236553/REG 727 in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy J Am Coll Cardiol 59 2012 2344 2353
39. J. Robinson Odyssey long term trial with alirocumab Presented at AHA Nov 2014 2014 Available at: www.esccardio.org